Castle Biosciences won approval for a dual listing on the new Nasdaq Texas, while keeping its primary listing on the Nasdaq Global Market. The move could widen

Castle Biosciences won approval for a dual listing on the new Nasdaq Texas, while keeping its primary listing on the Nasdaq Global Market. The move could widen investor access and liquidity as the Dallas-based exchange launches; Q2 2026 revenue was $103.5 million.